Background-Intravascular ultrasound (IVUS)-attenuated plaque is characterized by absence of ultrasound signal behind hypoehcoic plaque and is seen almost exclusively in acute coronary syndromes.
I ntravascular ultrasound (IVUS)-attenuated plaques have been reported more commonly in patients with STelevation myocardial infarction (STEMI) than stable angina and have been associated with no reflow or deterioration in coronary blood flow after percutaneous coronary intervention (PCI). [1] [2] [3] [4] [5] Histological studies have shown that attenuated plaques contain more necrotic core and fibrofatty tissue or microcalcification compared with fibrous plaques without attenuation. 4, 6, 7 However, there are limited data on the evolution of attenuated plaques over time.
The aim of the present study was to evaluate the natural evolution of attenuated plaques and their effect on vessel responses to stent implantation in patients with STEMI undergoing primary PCI.
Methods

Study Population
HORIZONS-AMI was a dual-arm, factorial, randomized trial in patients with STEMI. There were 2 randomization steps: (1) unfractionated heparin plus routine GPIIb/IIIa inhibition versus bivalirudin alone (1:1 randomization) and (2) TAXUS EXPRESS paclitaxeleluting stents (PES) versus EXPRESS bare metal stents (BMS) (3:1 randomization). The detailed inclusion and exclusion criteria and study procedures have been previously reported. 8 Among patients undergoing stent randomization, 13-month angiographic follow-up
WHAT IS KNOWN
• Intravascular ultrasound (IVUS)-attenuated plaques are more common in patients with acute coronary syndromes than stable angina and within the spectrum of acute coronary syndrome, more common in ST-elevation myocardial infarction STEMI than non-ST-elevation myocardial infarction. • IVUS-attenuated plaques are associated with distal embolization during stent implantation whether documented by no-reflow, deterioration in coronary blood flow, or biomarker elevation. • When compared with virtual histology IVUS, near infrared spectroscopy, or optical coherence tomography, IVUS attenuation is a marker of a large necrotic core or lipid rich plaque, a thin-cap fibroatheroma, thrombus, or microcalcification.
WHAT THE STUDY ADDS
• When attenuated plaques were stented, there was significant tissue/thrombus protrusion through stent struts. • When studied using serial (baseline and follow-up) IVUS, attenuated plaques evolved over time to become less attenuated and more calcified whether covered with a bare metal stent (BMS) or a paclitaxel-eluting stent (PES). • When stented, attenuated plaques were associated with less neointimal hyperplasia (BMS and PES), more late acquired stent-vessel wall malapposition (PES, but not BMS), and less need for repeat revascularization.
was prespecified for 1800 patients in whom acute stent implantation was successful (diameter stenosis Ͻ10% with TIMI-3 flow with NHLBI type A or less peri-stent dissection) and in whom neither stent thrombosis occurred nor bypass surgery was performed within 30 days. This study was approved by the institutional review boards of the institutions in which the procedures were performed, and written informed consent was obtained from all patients before cardiac catheterization. Major adverse cardiac events (MACE) included death, reinfarction, stroke, and ischemia-driven target vessel revascularization (TVR), as reported previously. 8
Quantitative and Qualitative Coronary Angiography
Coronary angiograms at baseline, immediately after PCI, and at follow-up were performed in at least 2 orthogonal views after intracoronary nitroglycerin. Angiograms were analyzed at the Angiographic Core Laboratory of the Cardiovascular Research Foundation (New York City, NY), using the CMS-GFT algorithm (MEDIS, Leiden, The Netherlands). Minimum lumen diameter (MLD) and average reference vessel diameter (RVD), obtained by averaging 5-mm segments proximal and distal to the target-lesion location were used to calculate diameter stenosis (DS) [(1ϪMLD/ RVD)ϫ100]. Binary restenosis was defined as a Ն50% diameter stenosis. Qualitative analysis was done using standard, published methods. 9
IVUS Imaging and Analysis
IVUS sites were preselected on the basis of their desire to participate in this substudy and their agreement to perform baseline (poststent) and follow-up IVUS on consecutive patients in the angiographic follow-up cohort until at least 300 consecutive IVUS cases were completed. The primary prespecified IVUS end point was the in-stent percent net volume obstruction at follow-up, as previously described. 10 Allowable IVUS systems included iLab, Galaxy, or ClearView (all with Atlantis SR Pro, 40-MHz catheters [Boston Scientific, Fremont, CA]) or In Vision Gold with 20-MHz EagleEye catheters (Volcano Corporation, Rancho Cordova, CA) as long as the same system was used at baseline and follow-up. IVUS imaging was performed after stent implantation using motorized pullback at 0.5 mm/s to include the stent and Ͼ5 mm segments proximal and distal to the stent. IVUS studies were archived onto s-VHS tape, CD-ROM, or DVD and sent to an independent, treatment allocationblinded, IVUS core laboratory (Cardiovascular Research Foundation, New York, NY) for quantitative and qualitative analyses using validated planimetry software (EchoPlaque, INDEC Systems, Inc, Mountain View, CA). Quantitative analysis included measurement of the external elastic membrane (EEM), stent, and lumen cross-sectional areas (CSA) every 1 mm. 11 Plaqueϩmedia CSA was calculated as EEM minus lumen. Neointimal hyperplasia (NIH) was calculated as stent minus lumen. Once a complete set of CSA measurements was obtained, intrastent and stent-edge volumes (EEM, plaqueϩmedia, stent, lumen, and NIH) were calculated by using the Simpson rule and normalized for stent or reference segment length as appropriate. Percent net volume obstruction was calculated as NIH divided by sent volume. Volumetric analysis was performed only for lesions in which motorized pullback was consistent and reliable.
Attenuated plaque was identified by the absence of the ultrasound signal behind plaque that was either hypoechoic or isoechoic to the reference adventitia but contained no echoes that were brighter than the adventitia (Figure 1 ). If there was a gap of at least 5 mm between attenuated plaques, they were considered to be multiple attenuated Figure 1 . Serial intravascular images from 4 different lesions containing noncalcified plaques with attenuation. A1 through A4, images at poststenting, B1 through B4, corresponding cross sections at follow-up. More calcium (arrow) was found in PES-stented cross section (B2) and BMS-stented cross section (B3) at follow-up, compared with corresponding images at poststenting (A2 and A3), whereas calcium did not increase significantly in proximal reference site (B1 compared with A1) or distal reference site (B4 compared with A4). Neointima hyperplasia could be seen in BMS stenting sites at follow-up (B3). PES indicates paclitaxel-eluting TAXUS stents; BMS, bare metal EXPRESS stents.
plaques. The identification and location of attenuated plaques required the agreement of two observers, one of whom was A.M. In each frame (mm by mm), an arc of attenuation was measured using the center of the lumen as the vertex. An attenuation score was assigned for each measured image: 0ϭno attenuated plaque, 1ϭattenuated plaque with acoustic shadowing Ͻ90°, 2ϭattenuated plaque with acoustic shadowing between 90 -180°, 3ϭattenuated plaque with acoustic shadowing between 180 -270°, and 4ϭattenuated plaque with acoustic shadowing Ͼ270°. Grading of 10 ran-domly selected attenuated plaques by 2 observers and by 1 observer at2 separate sessions showed an interobserver correlation coefficient of 0.955 and an intraobserver coefficient of 0.947.
The arc of calcium (highly echogenic area that was brighter than the adventitia and that caused acoustic shadowing with or without reverberations) was also measured and graded similarly as 0ϭno calcium, 1ϭcalcium Ͻ90°, 2ϭcalcium of 90 -180°, 3ϭcalcium of 180 -270°, and 4ϭcalcium of Ͼ270°. In addition, qualitative analysis (stent malapposition, plaque/thrombus protrusion, and other 
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Attenuated Plaque in AMI findings) was performed according to previous publications. 10 Stent malapposition was defined as a separation of at least 1 stent strut from the intimal wall not overlapping a side branch with evidence of blood speckling (indicating flow). Late acquired stent malapposition referred to malapposition that was not present after stent implantation but developed during the follow-up period.
Statistical Analysis
Statistical analysis was performed using SAS software, Version 9.1 (SAS Institute Inc, Cary, NC). Categorical variables were summarized as frequencies or percentages and were compared using 2 or Fisher exact tests. Continuous variables were compared using Wilcoxon rank-sum test and displayed as median and interquartile ranges. For lesion level data, a model with generalized estimating equations (GEE) approach was used to compensate for any potential cluster effect of multiple lesions in the same patient and presented as least-square means with 95% confidential intervals. The correlation between changes of attenuation score versus changes of calcium score was analyzed using Pearson correlation coefficient with GEE correction. The event analyses were performed with the use of time-to-event data (with data censored at the time of a patient's withdrawal from the study or at the last follow-up examination); the results of these analyses are shown with the use of Kaplan-Meier methods and were compared by means of the log-rank test. Statistical significance was set at PϽ0.05.
Results
Baseline Distribution of Attenuated Plaques
Between Baseline patient data are shown in Table 1 . There was no significant difference between the patients with or without attenuate plaque in either the PES or BMS group. Baseline and follow-up angiographic data are shown in Table 2 . Preintervention MLD was smaller in the lesions with attenuated plaque versus no attenuated plaque in both PES and BMS groups, and American Heart Association/American College of Cardiology lesion classification B 2 /C was similar in lesions with attenuated plaque versus no attenuated plaque in both groups. There was no difference in the presence of the thrombus between lesions with versus without attenuated plaque.
At baseline overall, 221 attenuated plaques in 137 lesions were detected; therefore, 70.3% (137/195) of study lesions contained at least one attenuated plaque, and 19.0% of lesions contained Ն2 attenuated plaques. Attenuated plaques were detected in 23.8% of proximal reference sites, 72.1% of PES-stented sites, 64.6% of BMS-stented sites, and 6.8% of distal reference sites. Overall, 49.6% of attenuated plaques were located in the left anterior descending coronary artery, 39.4% were located in the right coronary artery, and 11% were located in left circumflex artery. The length of the attenuated plaques measured 4.0 [1.0, 6.0] mm in the proximal reference sites, 9.8 [4.1, 15 .0] mm in PES-stented 
IVUS Evolution of Attenuated Plaques
Among 137 lesions with at least 1 attenuate plaque at baseline, attenuated plaque decreased in 118 (86.1%) lesions, increased in 8 (5.8%) lesions, and disappeared entirely in 11 (8.0%) lesions at follow-up. There were 3 new attenuated plaques where none had existed at baseline (length 4.2 [6.0, 7.8] mm). During the follow-up period, attenuation scores decreased significantly in distal reference segments and within PES and BMS sites, but with no difference between PES-and BMS-treated lesions (Figure 2) .
The decrease in attenuation was accompanied by an increase in calcification, with no differences between the 2 stent types ( Table 3 ). There were more changes in calcium score from baseline to follow-up in attenuated plaque segments versus nonattenuated plaque segments in both PES sites (increase in calcium score of 4.4[3.3, 5.5] in attenuated segments versus 1.6 [0.9, 2.3] in nonattenuated segments, PϽ0.0001) and in BMS sites (4.1 [2.3, 5.9] versus 1.0 [0.3, 1.7], Pϭ0.001), but such a trend was not seen in reference segments ( Table 4 ). An example is shown in Figure 1 . Changes in attenuation scores correlated with changes in calcium scores in both PES sites (Pearson correlation coeffi-cientϭϪ0.456, PϽ0.0001) and BMS sites (Pearson correlation coefficientϭϪ0.450, Pϭ0.0006) (Figure 3 ).
Effect of Attenuated Plaque on Quantitative and Qualitative Vascular Responses to Stent Implantation
The relationship between attenuated plaque and poststent IVUS findings is summarized in Table 5 . Attenuated and nonattenuated plaques were treated with the similar stent lengths but larger stent diameters. There was no adverse effect of attenuated plaque on minimum lumen area or the incidence of acute stent malapposition. There was no difference between the rates of resolution of acute stent malapposition comparing attenuated plaques versus nonattenuated plaques either in lesions treated with PES or BMS. There was also no difference in persistent versus resolved acute malapposition with regards to changes in calcium score or changes in attenuation score.
There was more plaque/thrombus protrusion in PEStreated attenuated plaques (77.4%) versus 59.0% in PEStreated nonattenuated plaques (Pϭ0.07), with a similar trend in BMS-treated attenuated plaques (67.7% versus 47.1% in BMS-treated nonattenuated plaques, Pϭ0.20). All plaque/ thrombus protrusion resolved at follow-up.
At follow-up, PES implantation into attenuated plaques was particularly associated with late acquired stent malapposition (36.8% versus 15.4% in nonattenuated plaques treated with PES, Pϭ0.03) ( Table 6 ). The association between attenuated plaques and late acquired stent malapposition was not seen in BMS-treated lesions although the number of lesions was small. There was also no difference in the rate of late acquired stent malapposition between PES-treated attenuated plaques that had an increase in calcification (nϭ72) compared with attenuated plaques that did not have an increase in calcification (nϭ34) (34.7% versus 41.2%, Pϭ0.52).
At follow-up, PES implantation into attenuated plaques was associated with less neointima formation compared with PES implantation into nonattenuated plaques; a similar trend was seen in BMS. In the PES group there was less neointima in attenuated plaque lesions that had an increase in calcification (nϭ72) compared with lesions that did not have an increase in calcification (nϭ34) 
Clinical Follow-Up Data
At 3 years of follow-up, there was no definite/probable stent thrombosis in this cohort. At 1 year, 4 MACE occurred, but only in the patients with attenuated plaque at baseline ( Table  7 ). The majority (84%) of MACE occurred between one and 3 years. Target lesion revascularization was significantly more common in patients without attenuated plaque compared with patients with attenuated plaque (17.4% versus 6.0%, Pϭ0.019). Reinfarction occurred only in patients with attenuated plaque although the numbers were small (3 patients). We also compared the clinical outcome based on the existence of attenuated plaque at follow-up (attenuated plaque at follow-up in 116 patients versus no attenuated plaque at follow-up in 70 patients), and the trend was similar to the impact of attenuated plaque at baseline.
Discussion
The present IVUS study demonstrates the evolution of attenuated plaques and the interaction between attenuated plaques and subsequent vascular responses to stent implantation in STEMI patients. Our results show a decrease in attenuation accompanied by an increase in calcification 13 months after either PES or BMS implantation, and this process was associated with less neointima hyperplasia and more malapposition after PES implantation.
In our study, attenuated plaques were found in 70.3% of target lesions in STEMI patients, much higher than in previous studies of acute coronary syndrome patients. 1 (1) In our study, all patients underwent primary PCI, and no thrombolytics were used, whereas in 1 previous study approximately 30% of patients received thrombolytic treatment before IVUS imaging that might have affected the frequency of thrombus formation and plaque attenuation. (2) In previous studies, IVUS imaging was performed before PCI. [1] [2] [3] [4] 
Pathological Explanations for Attenuated Plaque and Their Natural History
Pathological studies and in vitro experiments suggest that attenuation is a result of (1) microcalcification in unstable plaques causing ultrasonic wave reflection and dispersion 7 or (2) thrombus formation. 12 The natural history of attenuated plaques is not fully understood. One radiofrequency-IVUS study has shown that grayscale IVUS attenuated plaques are associated with a larger VH-IVUS necrotic core that often contains microcalcifications. 13 This has been supported by IVUS studies showing little macrocalcium in culprit lesions of ACS patients compared with stenoses of patients with stable angina. 14, 15 A recent study showing preatheroma microcalcifications is consistent with this hypothesis. 16 Thus, microcalcifications within attenuated plaque may coalesce at follow-up to result in macroscopic calcium as was seen in our study. In support of this, previous pathological studies have shown that coronary calcium tends to be related to the presence of healed previous plaque ruptures or to the devolutionary course of a vulnerable plaque and/or a necrotic core. 17 The contribution of calcification of attenuated plaques to plaque stabilization (or destabilization) must be elucidated by future study. Minimal lumen area, mm 2 6.5 (6.2, 6.9) 6.7 (6.0, 7.5) 0.65 7.0 (6.5, 7.5) 6.0 (5. Contrary to the current results, Bayturan et al 18 did not find significant changes in attenuated plaques at the time of follow-up IVUS. However, the patients in this report were enrolled in serial IVUS progression/regression studies; all of the patients in this report had stable angina, only nonculprit and nonstenotic segments were analyzed, and none of the analyzed lesions were stented. Thus, the patient populations and coronary arterial segments were very different from the stented culprit lesions in acute myocardial infarction (AMI) patients that are reported in the current study. However, similar to the study by Bayturan et al, we did find attenuated plaques in reference sites to be relatively stable.
Vascular Responses After Attenuated Plaques Are Treated With BMS or PES
Previous pathological studies have shown that PES delay arterial healing and that this delay in healing is characterized by persistent fibrin deposition and poorer endothelialization compared with BMS. 19 However, the relationship between plaque types and healing after PES implantation has not been well studied other than an adverse effect of strut penetration into a large necrotic core that increases the risk of late thrombotic complications 20 and delayed healing in AMI patients compared with stable angina patients. 21 In the present study, neointima hyperplasia was quantitatively less common and late acquired stent vessel wall malapposition was more common in PES-treated attenuated plaques than PES-treated nonattenuated plaques. The relationship between late stent malapposition and less neointimal hyperplasia has been reported previously. 22 The current study suggests that there is a complex interaction between IVUS attenuation as a marker for plaque composition and vascular responses to PES stents that deserves further study. Although patient numbers in this IVUS substudy were small, we still found a significant difference in target lesion revascularization between patients with attenuated plaques versus patients without attenuated plaques consistent with the reduction in neointimal hyperplasia.
Study Limitations
Patient numbers in this IVUS substudy were limited, with few adverse events during follow-up; therefore, we could not find a relation between the ultrasound evolution of attenuated plaques and clinical events, although there was a relation between the baseline presence of attenuated plaque and clinical events. Not all patients in the HORIZON-AMI IVUS substudy were included because of image quality and missing follow-up IVUS. IVUS examination was performed using either 20-MHz or 40-MHz catheters in the present study. The frequency of IVUS attenuation and/or the attenuation score was affected by the frequency of the catheters; however, each patient was studied using the same equipment at baseline and follow-up.
Conclusions
Serial IVUS analysis in the HORIZON-AMI Trial showed that attenuated plaques were ubiquitous in culprit lesions in patients with AMI and that these plaques were associated with less intimal hyperplasia, more late acquired stent malapposition, and increased lesion-site calcification at follow-up.
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